ReviewJournal of magnetic resonance imaging : JMRI2026
The Role of Magnetic Resonance Spectroscopy (MRS), Diffusion-Tensor-Imaging (DTI) and Structural MRI in the Alzheimer's Disease and Mild Cognitive Impairment Diagnosis: A Review.
Review in Journal of magnetic resonance imaging : JMRI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is one of the most common neurological disorders affecting older adults, with approximately 7.2 million cases only in the United States. This number is projected to increase to 13.8 million in the United States by 2060, leading to increased expenditures for healthcare, long-term care and hospice services. Consequently, great emphasis is placed on prevention and the development of early diagnosis techniques, which can lead to timely treatment and the prevention of the consequences of full-blown disease. In this review, we analyze the potential diagnostic value of biomarkers derived from a multimodal approach based on magnetic resonance spectroscopy, diffusion tensor imaging, and magnetic resonance imaging, capable of detecting metabolic, microstructural, and anatomical changes, respectively, that precede the cognitive and behavioral changes observed in AD by years. The primary aim is to evaluate whether the combined and complementary use of these methods can identify early biomarkers useful for recognizing AD in its early stages, predicting progression from MCI to AD, supporting patient stratification, and monitoring cognitive decline or response to treatment. We identified regions more susceptible to metabolic alterations (PCC and hippocampus) and trajectories of structural brain alterations (atrophy or diffusivity abnormalities). The assessment of such imaging biomarkers may serve as the foundation for future prospective studies aimed at developing differential diagnostic methods, a crucial goal within the broader context of dementias, by adopting standardized multimodal MRI protocols. EVIDENCE LEVEL: 3. TECHNICAL EFFICACY: Stage 1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.